Switch theme
Sign up to access all valuation multiples
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three quarters of sales while the balance is generated from medical technology products that enable dialysis treatments.
1996
111.5K+
LTM Revenue $21.9B
LTM EBITDA $4.0B
$27.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Fresenius Medical Care has a last 12-month revenue (LTM) of $21.9B and a last 12-month EBITDA of $4.0B.
In the most recent fiscal year, Fresenius Medical Care achieved revenue of $21.7B and an EBITDA of $3.6B.
Fresenius Medical Care expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Fresenius Medical Care valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $21.9B | XXX | $21.7B | XXX | XXX | XXX |
| Gross Profit | $5.6B | XXX | $5.3B | XXX | XXX | XXX |
| Gross Margin | 26% | XXX | 25% | XXX | XXX | XXX |
| EBITDA | $4.0B | XXX | $3.6B | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 17% | XXX | XXX | XXX |
| EBIT | $2.1B | XXX | $1.6B | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | 8% | XXX | XXX | XXX |
| Net Profit | $819M | XXX | $604M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | 3% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $6.4B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Fresenius Medical Care's stock price is EUR 50 (or $57).
Fresenius Medical Care has current market cap of EUR 14.8B (or $16.6B), and EV of EUR 24.1B (or $27.1B).
See Fresenius Medical Care trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $27.1B | $16.6B | XXX | XXX | XXX | XXX | $3.76 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Fresenius Medical Care has market cap of $16.6B and EV of $27.1B.
Fresenius Medical Care's trades at 1.2x EV/Revenue multiple, and 7.5x EV/EBITDA.
Equity research analysts estimate Fresenius Medical Care's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Fresenius Medical Care has a P/E ratio of 20.3x.
See valuation multiples for Fresenius Medical Care and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $16.6B | XXX | $16.6B | XXX | XXX | XXX |
| EV (current) | $27.1B | XXX | $27.1B | XXX | XXX | XXX |
| EV/Revenue | 1.2x | XXX | 1.2x | XXX | XXX | XXX |
| EV/EBITDA | 6.8x | XXX | 7.5x | XXX | XXX | XXX |
| EV/EBIT | 13.0x | XXX | 16.4x | XXX | XXX | XXX |
| EV/Gross Profit | 4.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 20.3x | XXX | 27.5x | XXX | XXX | XXX |
| EV/FCF | 15.0x | XXX | 14.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialFresenius Medical Care's last 12 month revenue growth is 2%
Fresenius Medical Care's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $33K for the same period.
Fresenius Medical Care's rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Fresenius Medical Care's rule of X is 23% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Fresenius Medical Care and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | 19% | XXX | 19% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 23% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $33K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Fresenius Medical Care acquired XXX companies to date.
Last acquisition by Fresenius Medical Care was XXXXXXXX, XXXXX XXXXX XXXXXX . Fresenius Medical Care acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Fresenius Medical Care founded? | Fresenius Medical Care was founded in 1996. |
| Where is Fresenius Medical Care headquartered? | Fresenius Medical Care is headquartered in Germany. |
| How many employees does Fresenius Medical Care have? | As of today, Fresenius Medical Care has 111.5K+ employees. |
| Who is the CEO of Fresenius Medical Care? | Fresenius Medical Care's CEO is Dr. Katarzyna Mazur-Hofsaess, PhD. |
| Is Fresenius Medical Care publicy listed? | Yes, Fresenius Medical Care is a public company listed on ETR. |
| What is the stock symbol of Fresenius Medical Care? | Fresenius Medical Care trades under FME ticker. |
| When did Fresenius Medical Care go public? | Fresenius Medical Care went public in 1996. |
| Who are competitors of Fresenius Medical Care? | Similar companies to Fresenius Medical Care include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Fresenius Medical Care? | Fresenius Medical Care's current market cap is $16.6B |
| What is the current revenue of Fresenius Medical Care? | Fresenius Medical Care's last 12 months revenue is $21.9B. |
| What is the current revenue growth of Fresenius Medical Care? | Fresenius Medical Care revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Fresenius Medical Care? | Current revenue multiple of Fresenius Medical Care is 1.2x. |
| Is Fresenius Medical Care profitable? | Yes, Fresenius Medical Care is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Fresenius Medical Care? | Fresenius Medical Care's last 12 months EBITDA is $4.0B. |
| What is Fresenius Medical Care's EBITDA margin? | Fresenius Medical Care's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Fresenius Medical Care? | Current EBITDA multiple of Fresenius Medical Care is 6.8x. |
| What is the current FCF of Fresenius Medical Care? | Fresenius Medical Care's last 12 months FCF is $1.8B. |
| What is Fresenius Medical Care's FCF margin? | Fresenius Medical Care's last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of Fresenius Medical Care? | Current FCF multiple of Fresenius Medical Care is 15.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
